- Conditions
- Coronary Artery Disease
- Interventions
- Stem Cell Therapy, Control (plasma)
- Biological · Other
- Lead sponsor
- Texas Heart Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Taxane, Vinorelbine, Ixabepilone, Eribulin, Chemotherapy
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- FOLFOXA
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 2
- States / cities
- Fairhaven, Massachusetts • Providence, Rhode Island
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- SGT-53, nab-paclitaxel, Gemcitabine
- Genetic · Drug
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7
- Interventions
- Capecitabine, Laboratory Biomarker Analysis, Nab-paclitaxel, Questionnaire Administration, Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 5
- States / cities
- Houston, Texas • League City, Texas • Sugar Land, Texas + 1 more
- Conditions
- Transesophageal Echocardiography Contrast Agents
- Interventions
- normal saline, human albumin, human albumin and propofol
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Pre-Eclampsia
- Interventions
- Human Albumin (colloid), Lactated Ringer's Injection (crystalloid), Edwards HemoSphere monitor with ClearSight-Acumen finger cuff
- Drug · Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Cisplatin, Carboplatin, Pemetrexed, Nab-paclitaxel, Gemcitabine, Docetaxel, M7824, Bintrafusp alfa, Paclitaxel
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- Fountain Valley, California • San Marcos, California • Port Saint Lucie, Florida + 5 more
- Conditions
- Solid Tumor, Adult
- Interventions
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
- Combination Product
- Lead sponsor
- Trishula Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more
- Conditions
- Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
- Interventions
- CMV hyperimmune globulin, Placebo
- Drug · Other
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- Female only
- Enrollment
- 399 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2021
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more
- Conditions
- Breast Cancer
- Interventions
- Ipatasertib, Paclitaxel, Atezolizumab, Nab-Paclitaxel, AC
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Onvansertib, Gemcitabine, Nab-paclitaxel, Electrocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection, Computed Tomography
- Drug · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, nab paclitaxel, Onivyde, Leucovorin, 5-fu
- Drug
- Lead sponsor
- Benaroya Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 365
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 260 more
- Conditions
- Severe Sepsis, Septic Shock, Microcirculation
- Interventions
- Sidestream Dark Field (SDF), Near Infrared Spectroscopy (NIRS)
- Device
- Lead sponsor
- Mercy Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cancer
- Interventions
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
- Genetic · Other · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hemodynamic Stability
- Interventions
- Lactated Ringer's, 5% Human Albumin
- Drug
- Lead sponsor
- William C. Oliver
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure
- Interventions
- BVA-100
- Device
- Lead sponsor
- Daxor Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Bladder Cancer
- Interventions
- ABI-007, Carboplatin, Gemcitabine, Radical Cystectomy
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Cancer
- Interventions
- Abraxane alone, Abraxane + Tigatuzumab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Aging
- Interventions
- Sham, Therapeutic Plasma Exchange, IVIG
- Device · Drug
- Lead sponsor
- Dobri Kiprov
- Industry
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Mill Valley, California
- Conditions
- Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
- Interventions
- Idelalisib, Nab-paclitaxel, mFOLFOX6
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 6 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol, Radiation Therapy
- Biological · Drug · Radiation
- Lead sponsor
- GU Research Network, LLC
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
- Interventions
- Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Matthew Spector
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania